Use of Erythromycin in Mustard-Induced Bronchiolitis

NCT ID: NCT00367419

Last Updated: 2008-11-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We looked for the effectiveness of low-dose long-term prescription of erythromycin in mustard-induced bronchiolitis obliterans

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchiolitis Obliterans Acute Obliterating Bronchiolitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Erythromycin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented chemical exposure
* Clinical, spirometric and radiological findings were compatible with BO on High Resolution Computed Tomography (HRCT)
* Non-responsiveness to high dose bronchodilator therapy

Exclusion Criteria

* Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an infection that necessitated the use of an antibiotic
* History of cigarette smoking and occupational exposure to toxic agents of hypersensitivity to macrolides
* History of treatment with a systemic antibiotic within 7 days before the start of the study
* Any investigational medicine within 4 weeks of the study
* History of antibiotic injection within 6 weeks before the study
* Concomitant Theophylline or Carbamazepine, unless their serum concentrations were regularly monitored
* Patients who were in the exacerbation phase of their respiratory complications
* Need to use medications interact with macrolides such as Digoxin, Theophylline and Carbamazepine
* Systemic antibiotics
* Systemic Corticosteroids
* Admission to the hospital
* Abnormal kidney or liver function
Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Baqiyatallah Medical Sciences University

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mostafa Ghanei, Professor

Role: STUDY_DIRECTOR

Research Center of Chemical Injuries, Baqyatallah Medical Sciences University, Tehran, Iran

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Baqiyatallah Medical Sciences University

Tehran, Tehran Province, Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S-340-14-6-1-PU-02

Identifier Type: -

Identifier Source: org_study_id